 |
|
COMMENTS AND OPINIONS
The Management of Severe Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis—Reply
Julie Gueudry, MD;
Michel Binaghi, MD;
Marc Muraine, MD, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We appreciate the interest and comments of Sotozono et al regarding our article on the severity and management of ocular complications of SJS and TEN.1 Both conditions are recognized as 2 of the most devastating ocular surface diseases, and there is no standardized ophthalmologic treatment for the prevention of ocular complications.
Because accumulated clinical and experimental data suggest that the mechanisms of SJS and TEN depend on a medication-specific immune response, corticosteroids and immunosuppressive drugs are used by many physicians. However, these drugs are of unproven benefit at the acute stage, and their use remains highly controversial.2-3 Furthermore, results of retrospective analyses performed in several burn departments in the United States suggest that the prolonged use of high doses of systemic corticosteroids is associated with increased mortality.4 That is why we noted in our discussion1 that current management . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
The Management of Severe Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Chie Sotozono, Mayumi Ueta, and Shigeru Kinoshita
Arch Dermatol. 2009;145(11):1336-1337.
EXTRACT
| FULL TEXT
|
